

Australia's Myrio Therapeutics teams up with University of Pennsylvania and NYU to advance solid tumour immunotherapy

31 October 2025 | News

To accelerate the development of next-generation T cell immunotherapies



Australia-based Myrio Therapeutics has announced a collaborative research partnership with the University of Pennsylvania's Perelman School of Medicine and NYU Langone Health, in the US, to accelerate the development of next generation solid tumor T cell immunotherapeutics.

This tri-party agreement brings together complementary expertise in peptide HLA (pHLA) binder discovery, bispecific T-cell engager development and cell immunotherapies to overcome barriers to effective and durable immunotherapies through three core pillars:

- **Targeting Oncogenic Drivers:** Leveraging highly specific anti pHLA antibodies to directly attack the molecular drivers of cancer.
- **Amplifying Innate Immune Functions:** Coordinating approaches to harness and enhance the body's natural immune defenses.
- **Utilizing Novel CAR Architectures:** Co-developing next-generation Chimeric Antigen Receptors (CARs) with heightened sensitivity to a broader range of targets, including those with low abundance.

By combining their strengths, the three parties will generate deeper insights into these mechanisms and explore the therapeutic potential of these technologies. The next step will be to formally establish a company and initiate seed funding to move these advances toward clinical development.

“A major challenge in the development of cancer treatment is creating tolerable approaches that also deliver effective and long-lasting response in patients,” said Daniel J Powell Jr. Ph.D., a professor of Pathology and Laboratory Medicine in the Perelman School of Medicine at the University of Pennsylvania. “By uniting the diverse expertise of these three groups, we are in an excellent position to create safe, effective, durable therapy for difficult-to-treat cancers.”